Form 4: Quince Therapeutics Director Receives Stock Options in Lieu of Cash Retainer

Margaret McLoughlin, a director at Quince Therapeutics, received stock options in lieu of her 2025 annual cash retainer.

Summary

• Margaret McLoughlin, a director at Quince Therapeutics, was granted 31,613 stock options on January 2, 2025.
• These options were granted in lieu of her annual director cash retainer for 2025.
• The options have an exercise price of $1.88 per share.
• The options vest in equal quarterly installments over a one-year period.
• The options expire on January 2, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.

Positives

• The director's decision to take stock options instead of cash may align her interests more closely with shareholders.
• The vesting schedule encourages long-term commitment from the director.

Management Comments

• The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.

Industry Context

It is common practice for companies to offer stock options to directors as part of their compensation packages, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across the biotechnology industry, often used to incentivize performance and align interests with shareholders.
• The vesting schedule of one year is also a common practice, ensuring that directors have a long-term stake in the company's success.
• The exercise price of $1.88 is specific to Quince Therapeutics and would need to be compared to other similar companies to determine if it is in line with industry standards.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's long-term performance.
• The director is incentivized to contribute to the company's success due to the stock options.

Key Dates

Keywords

stock options, director compensation, insider trading, Quince Therapeutics, QNCX, equity, vesting